SAB-142 targets beta-cell preservation in newly diagnosed T1D; the SAFEGUARD Phase 2b readout will determine whether Phase 1 C-peptide signals translate to registrational efficacy

Updated 246d ago

SAB Biotherapeutics is a clinical-stage company developing a cell therapy to preserve insulin-producing beta cells in newly diagnosed type 1 diabetes, not yet approved.

SAB-142 is a hyperimmune polyclonal antibody designed to induce immune tolerance and preserve C-peptide in newly diagnosed Stage 3 autoimmune type 1 diabetes. The thesis resolves on whether SAFEGUARD Phase 2b demonstrates statistically significant C-peptide preservation meeting a registrational endpoint. The primary competitive threat is teplizumab (Tzield, Provention Bio/Sanofi), the only approved T1D disease-modifier, which sets a high clinical and commercial bar SAB-142 must clear or differentiate against.

Status

Intact

Conviction

What could change the thesis?

Phase 1 C-peptide signals in 4 patients may not replicate in the larger, more heterogeneous SAFEGUARD Phase 2b population, leaving the company with no approved product and diminishing cash well before any Phase 3 could be initiated.

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

1 programs · 3 catalysts

Stress Test